Nine-Year Outcome of Ranibizumab Monotherapy for Choroidal Neovascularization Secondary to Pathologic Myopia.

Abstract

PURPOSE:

The aim of this study was to evaluate the 9-year outcome of ranibizumab monotherapy for myopic choroidal neovascularization (mCNV).

METHODS:

This was a retrospective, nonrandomized, multicentric study to evaluate the long-term outcomes of mCNV treated with ranibizumab monotherapy for at least 9 years according to a strict pro re nata regimen.

RESULTS:

Seventeen eyes of 17 patients (12 women, mean age 57.9 ± 7.7 years) were included. The mean follow-up period was 112.4 ± 3.9 months (range 108-120). The mean difference in best-corrected visual acuity (BCVA) from baseline to the last follow-up was +1.2 ± 15.6 ETDRS letters (p = 0.004, between initial vs. 12 and 24 months). The mean total number of intravitreal injections for each patient was 1.24 ± 1.70 per year (range 2-25). No systemic adverse reactions related to the drug treatment were detected during the 9-year follow-up period.

CONCLUSIONS:

Long-term ranibizumab monotherapy treatment induces unchanged or better BCVA compared to baseline after a 9-year treatment in almost all eyes.

• Authors: Marco R Pastore, Vittorio Capuano, Elsa Bruyère, Alexandra Miere, Eleonora Corbelli, Lea Querques, Daniele Tognetto, Francesco Bandello, Giuseppe Querques, Eric H Souied
• Journal: Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde (Ophthalmologica) Vol. 239 Issue 2-3 Pg. 133-142 ( 2018) ISSN: 1423-0267 [Electronic] Switzerland
• PMID: 29268267 (Publication Type: Journal Article, Multicenter Study)
• Copyright: © 2017 S. Karger AG, Basel.

Chemical References

• Angiogenesis Inhibitors
• Vascular Endothelial Growth Factor A
• Ranibizumab

Topics

• Angiogenesis Inhibitors (administration & dosage)
• Choroidal Neovascularization (drug therapy)
• Female
• Fluorescein Angiography
• Fundus Oculi
• Humans
• Intravitreal Injections
• Male
• Middle Aged
• Myopia, Degenerative (complications, diagnosis, physiopathology)
• Ranibizumab (administration & dosage)
• Retrospective Studies
• Time Factors
• Tomography, Optical Coherence
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity